Cure8 research brief
Why This Matters
People with Crohn’s disease on anti‑TNF biologics can rarely develop severe infections that trigger life‑threatening hyperinflammatory syndromes like HLH. Early recognition and bone marrow testing can identify treatable infections such as Leishmania and guide lifesaving therapy and subsequent IBD management choices.
Who Should Pay Attention
Adult patients with Crohn’s disease on anti‑TNF therapy, gastroenterologists, infectious disease specialists, and hospital clinicians evaluating unexplained fever with cytopenias.
Study Snapshot
What To Know
This is a case report of a 31-year-old man with Crohn’s disease on escalated anti-TNF therapy who developed hemophagocytic lymphohistiocytosis (HLH) triggered by visceral leishmaniasis. Bone marrow showed hemophagocytosis and Leishmania amastigotes; treatment with liposomal amphotericin B led to resolution.
Anti-TNF was stopped and the patient was switched to an anti–IL-12/23 biologic for IBD control.
Keep In Mind
This report is a single-case clinical report from an academic journal. Visceral leishmaniasis is uncommon outside endemic areas, so clinicians should consider travel/exposure history. The article describes management in one patient and does not provide broader outcome data or comparative evidence.
Source Details
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.